SBIR Phase II: Novel Titanium Tantalum Materials for Improved Biomedical Implants and Medical Devices

SBIR 第二阶段：用于改进生物医学植入物和医疗器械的新型钛钽材料

• 批准号: 0724433
• 负责人: Harvey Fisher
• 金额: --
• 依托单位: DYNAMET TECHNOLOGY INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0724433&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Novel; Titanium

This Small Business Innovation Research (SBIR) Phase II project will use Titanium-Tantalum (Ti-TA) alloys, with the objective that these materials will become commercial alloys used in orthopaedic and stinting devices. Ti-30Ta has potential as a highly biocompatible implant alloy with a modulus closer to that of bone (thus mitigating bone shielding), and is potentially less notch-sensitive than standard titanium implant alloys. This project will also demonstrate that advanced powder metallurgy can produce novel titanium alloys that are extremely difficult and prohibitively expensive to produce by other means. Critical material property data of these alloys will be generated that will lead medical device manufacturers to incorporate these alloys into specific devices and to conduct the necessary testing and clinical trials for commercial product release. The broader impacts from the use of Ti-Ta alloys will enable the development of improved medical devices that will last longer; are less invasive, promote faster patient recovery times and minimize the risk of adverse reactions. Advances in orthopedic and cardiovascular products will also significantly reduce short-term and long-term health care costs associated with such medical conditions and surgical procedures. Ti-Ta materials will also offer advantages for non-biomedical applications, in regard to mechanical properties as well as to shape memory and superelastic properties. For example, such materials can be expected to also offer improved properties such as resistance to corrosion, oxidation and high temperatures. Thus, availability of these alloys will be applicable to a wide variety of industrial, consumer and aerospace products in addition to biomedical applications, resulting in significant commercial potential.

该小型企业创新研究（SBIR）第二阶段项目将使用钛钽（Ti-TA）合金，目的是使这些材料成为骨科和矫形器械中使用的商业合金。Ti-30 Ta具有作为高度生物相容性植入物合金的潜力，其模量更接近于骨的模量（从而减轻骨屏蔽），并且可能比标准钛植入物合金的缺口敏感性更低。该项目还将证明，先进的粉末冶金技术可以生产出用其他方法生产极其困难和昂贵的新型钛合金。将生成这些合金的关键材料属性数据，这些数据将引导医疗器械制造商将这些合金纳入特定器械，并为商业产品发布进行必要的测试和临床试验。使用钛钽合金的广泛影响将使改进的医疗器械的开发能够持续更长时间;侵入性更小，促进患者更快的恢复时间，并最大限度地降低不良反应的风险。骨科和心血管产品的进步也将大大降低与此类医疗条件和外科手术相关的短期和长期医疗保健成本。Ti-Ta材料还将在机械性能以及形状记忆和超弹性性能方面为非生物医学应用提供优势。例如，可以预期这样的材料还提供改进的性能，例如耐腐蚀性、耐氧化性和耐高温性。因此，除了生物医学应用之外，这些合金的可用性将适用于各种各样的工业、消费者和航空航天产品，从而产生显著的商业潜力。